Your session is about to expire
← Back to Search
Pelabresib for Myelofibrosis (MANIFEST-2 Trial)
MANIFEST-2 Trial Summary
This trial is testing a new drug, pelabresib, to see if it is better than the current best drug, ruxolitinib, for myelofibrosis patients who have not yet been treated with Janus kinase inhibitors.
MANIFEST-2 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMANIFEST-2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.MANIFEST-2 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with myelofibrosis.I have been diagnosed with myelofibrosis.My blood, kidney, and liver functions are all within normal ranges.My condition is rated Intermediate-1 or higher on the DIPSS scale.I have had symptoms scoring 3 or more on average, or a total score of 10 or more, in the last week.I can take care of myself and am up and about more than half of my waking hours.I have had my spleen removed or treated with radiation in the last 6 months.I am 18 years old or older.My condition is rated Intermediate-1 or higher on the DIPSS scale.My spleen is enlarged, measuring 450 cm^3 or more.I can take care of myself but might not be able to do heavy physical work.I've had symptoms scoring 3 or more on average, or a total score of 10 or more, in the last week.I don't have any health conditions or take medications that would stop me from receiving treatment.My spleen is enlarged, measuring 450 cm^3 or more.My condition is rated Intermediate-1 or higher on the DIPSS scale.My blood, kidney, and liver functions are all within normal ranges.I have been treated with JAKi or BET inhibitors for a blood disorder.I have been diagnosed with myelofibrosis.My blood, kidney, and liver functions are all within normal ranges.I am 18 years old or older.I've had symptoms scoring 3 or more on average, or a total score of 10 or more, in the last week.My spleen is enlarged, measuring 450 cm^3 or more.I am 18 years old or older.
- Group 1: Pelabresib + ruxolitinib
- Group 2: Placebo + ruxolitinib
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What have been the recorded side effects of CPI-0610?
"Given that this is a Phase 3 trial with supporting efficacy data as well as multiple rounds of safety data, our team has rated CPI-0610's safety at a 3."
How many people fit the requirements to participate in this clinical trial?
"In order to carry out this clinical trial, 400 individuals that meet the inclusion criteria will be needed. The sponsor, Constellation Pharmaceuticals, plans to execute the study at different locations including Franciscan Health/Indiana blood and Marrow Transplantation in Indianapolis, Indiana and Moffitt Cancer Center in Tampa, Florida."
Could you tell me if there has been prior research involving CPI-0610?
"CPI-0610 was first studied in 2002 at the National Institutes of Health Clinical Center. To date, there have been a total of 18378 completed studies with 99 ongoing trials. Many of these live studies are taking place in Indianapolis, Indiana."
What conditions does CPI-0610 show the most promise in treating?
"CPI-0610 is an effective treatment for polycythemia vera, polycythemia, and patients who cannot tolerate or have developed resistance to hydroxyurea."
Are there still places available for people who want to participate in this trial?
"Yes, the information on clinicaltrials.gov point out that this clinical trial is currently searching for candidates. The clinical trial was initially posted on 11/19/2020 and was most recently edited on 10/10/2022. The trial is admitting 400 patients across 36 sites."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Summit Medical Group - Cancer Center: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger